Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
Lancet
; 1(8638): 577-80, 1989 Mar 18.
Article
em En
| MEDLINE
| ID: mdl-2564111
ABSTRACT
Tumour-infiltrating lymphocytes (TIL) were isolated and expanded from small tumour biopsy samples of twenty-eight patients (thirteen with malignant melanoma, seven with renal cell carcinoma, and eight with non-small-cell lung cancer). The patients were treated with autologous expanded TIL (about 10(10)) and continuous infusions of recombinant human interleukin-2(1-3 x 10(6) U/m2 per 24 h). 29% of the patients with renal cell cancer and 23% of those with melanoma achieved objective tumour responses lasting 3-14 months. Toxic side-effects were limited, and no patient required intensive-care monitoring. Adoptive immunotherapy with TIL and interleukin-2 may be an effective systemic approach to the treatment of some patients with malignant melanoma and renal cell carcinoma.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Linfócitos T
/
Interleucina-2
/
Carcinoma de Células Pequenas
/
Neoplasias Renais
/
Neoplasias Pulmonares
/
Melanoma
Idioma:
En
Ano de publicação:
1989
Tipo de documento:
Article